Back in February, a study showed the variability of immune responses in different people with multiple sclerosis (MS) and suggested this heterogeneity affected responses to the commonly prescribed MS medication interferon-β, but blood biomarkers may exist that can help to determine those most likely to benefit from such treatment.
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.